Aurobindo Pharma received final USFDA approval for Rivaroxaban Tablets USP, 2.5 mg, a generic equivalent to XARELTO. The US market for this strength is valued at $447 million. Aurobindo also received tentative approval for 10 mg, 15 mg, and 20 mg strengths, whose combined US market is $8.5 billion. This approval brings Aurobindo's total USFDA approvals to 540.